MLTX MoonLake Immunotherapeutics
- 44.520
- -0.740-1.63%
- 44.520
- 0.0000.00%
MoonLake Immunotherapeutics News
MoonLake Immunotherapeutics' Sonelokimab Shows Promise in Psoriatic Arthritis and HS, Meriting a Buy Rating
Strong Buy Rating for MoonLake Immunotherapeutics Based on Promising Sonelokimab Clinical Trials and Market Potential
MoonLake Analyst Ratings
HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target
Buy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Clinical Results for Sonelokimab
HC Wainwright & Co. : MoonLake (MLTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $100.00.
MoonLake Analyst Ratings
MoonLake Immunotherapeutics Buy Rating: Strategic Partnerships and Market Potential Fuel Optimism
Needham: Revised MoonLake (MLTX.US) rating, adjusted from buy to buy rating, target price $66.00.
MoonLake Analyst Ratings
Needham Reiterates Buy on MoonLake, Maintains $66 Price Target
MoonLake Analyst Ratings
Analysts' Top Healthcare Picks: Argenx Se (ARGX), MoonLake Immunotherapeutics (MLTX)
MoonLake Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Aligos Therapeutics (ALGS)
Analysts Offer Insights on Healthcare Companies: Geron (GERN), Merus (MRUS) and MoonLake Immunotherapeutics (MLTX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Janux Therapeutics Inc (JANX) and SAGE Therapeutics (SAGE)
MoonLake Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), MoonLake Immunotherapeutics (MLTX) and Wave Life Sciences (WVE)
MoonLake Analyst Ratings
Analysis
Price Target
No Data
